2023 World Conference on Lung Cancer (Posters)-P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study)

P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study) - PDF(Abstract)

Back to course

Pdf Summary

The study presented at WCLC 2023 focused on the real-world use and outcomes of osimertinib, a drug used for the first-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC). The study aimed to understand the effectiveness and safety of osimertinib and the patterns of disease progression in a Japanese population.<br /><br />The study enrolled 659 NSCLC patients who were treated with EGFR tyrosine kinase inhibitors (TKIs), with 88% of them receiving osimertinib monotherapy. The median age of the patients was 72 years, and there was a slightly higher proportion of female patients. The most common mutation types were exon19 deletion and exon21 L858R point mutation. The observation period for patients treated with osimertinib ranged from 0.1 to 48.0 months.<br /><br />The study found that osimertinib had an overall objective response rate of 68.3%, median progression-free survival of 20.0 months, and overall survival of 41.0 months. Patients with exon 19 deletion had better progression-free and overall survival compared to those with exon21 L858R mutation. Grade 3 or worse adverse events were observed in 23.3% of patients, and discontinuation due to toxicities was seen in 15.9% of patients. Pneumonitis was observed in 12.9% of patients.<br /><br />In terms of disease progression patterns, the study categorized patients into central nervous system-only, oligo-progression, and multiple organ progression. The majority of patients experienced oligo-progression. Survival after disease progression with osimertinib varied depending on the progression pattern and patients' clinical condition.<br /><br />The study concluded that first-line osimertinib demonstrated good effectiveness in real-world clinical practice. However, it was suggested that osimertinib should not be used beyond disease progression. The findings of this study provide valuable insights into the use of osimertinib in the Japanese population and can contribute to the understanding of treatment outcomes in real-world settings.

Asset Subtitle

Kageaki Watanabe

Meta Tag

Speaker Kageaki Watanabe

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

WCLC 2023

osimertinib

EGFR mutation-positive non-small cell lung cancer

real-world use

effectiveness

safety

Japanese population

EGFR tyrosine kinase inhibitors

exon19 deletion

exon21 L858R point mutation